Frontage Laboratories (Shanghai) Co., Ltd.

Frontage Laboratories (Shanghai) Co., Ltd. is a leading Contract Research, Development, and Manufacturing Organization (CRDMO) and a key subsidiary of the publicly traded Frontage Holdings Corporation. Established in 2005, the company operates as a critical hub for the group's Asia-Pacific operations, providing integrated, science-driven research and analytical services. Its core capabilities span the entire drug discovery and development lifecycle, including bioanalysis, drug metabolism and pharmacokinetics (DMPK), safety and toxicology, and chemistry, manufacturing, and control (CMC) services. The company is recognized for its 'One-Stop Shop' model, which allows pharmaceutical and biotechnology clients to transition seamlessly from discovery to early-phase clinical trials. Frontage Shanghai maintains high-standard facilities that are compliant with global regulatory requirements, including those of the US FDA and China's NMPA. Through strategic acquisitions and internal expansion, the company has bolstered its expertise in complex modalities such as cell and gene therapy, oligonucleotides, and antibody-drug conjugates (ADCs), positioning itself as a premier partner for both global pharmaceutical giants and emerging biotech innovators.